Weight Management News and Research

RSS

Could GLP-1 drugs help women with PCOS beyond weight loss?

A scoping review of 28 studies suggests that GLP-1 receptor agonists may improve androgen levels and menstrual function in women with polycystic ovary syndrome (PCOS), alongside their established metabolic benefits. Evidence for improved ovulation, fertility, and pregnancy outcomes remains limited, and the researchers could not determine whether reproductive benefits result directly from the drugs or from weight loss and improved metabolic health.

1 Nov 2026

New framework guides safer obesity drug prescribing in older adults

Today, the American Geriatrics Society (AGS) released a new framework to assist clinicians to safely prescribe obesity medications in older adults.

29 Oct 2026

Thyroid cancer risks and medication timing with oral GLP-1s

Like most prescriptions, glucagon-like peptide 1 (GLP-1) medications to manage weight come with potential risks.

28 Oct 2026

Taking a GLP-1 drug? Here's what the safety evidence really shows

A review on GLP-1 receptor agonists highlights risks like pancreatitis and thyroid cancer, emphasizing individual patient risk over general safety concerns.

26 Oct 2026

Can happy feelings trigger eating too? Researchers explored both sides of emotional eating

Among 3,834 members of weight-management programs, greater recent weight loss was associated with less emotional eating, fewer food cravings, and better mood. Participants identified distraction, meal planning, healthier food swaps, and group support as helpful strategies, but the observational study could not establish whether these approaches caused weight loss.

25 Oct 2026

Emotion management helps teens maintain weight loss after treatment

Researchers from University of California San Diego have found that adding emotion management skills to family-based behavioral weight management may help adolescents maintain weight loss after treatment ends.

22 Oct 2026

Why the same healthy diet may not work the same way for everyone

A review published in Nutrients proposes a seven-pillar precision nutrition framework that combines biological, behavioral, and environmental information to tailor dietary interventions throughout life. The authors identify potential benefits for cardiovascular, respiratory, blood, and sleep health, while emphasizing the need for further clinical trials to establish effective, accessible, and personalized nutritional strategies.

20 Oct 2026

GLP-1 drugs may protect kidney health in people with bipolar disorder

Mayo Clinic researchers found that GLP-1 receptor agonists, medications widely used for diabetes and weight management, were associated with a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease.

20 Oct 2026

Could this flowering plant help people lose body fat?

Lythrum salicaria extract supplementation led to body fat reduction in a clinical trial, suggesting a promising plant-based approach to weight management.

19 Oct 2026

Losing weight is one thing. Keeping your muscle is another, experts say

The International Society of Sports Nutrition (ISSN) position stand concludes that sustained calorie restriction drives weight loss, while adequate protein intake and resistance training help preserve lean mass. Reviewing intermittent fasting, ketogenic diets, and other dietary approaches, the authors emphasize individualized nutrition plans, body composition, and sustainable weight management rather than rapid weight loss alone.

14 Oct 2026

Doctors avoided two common words when talking about weight with patients

Researchers analyzed 123 recorded primary care consultations involving adults with type 2 diabetes and elevated BMI, finding that weight was discussed in just 39% of visits. Clinicians avoided potentially stigmatizing terms such as "overweight" and "obesity," while weight-related conversations occurred more frequently among patients taking GLP-1 receptor agonists.

13 Oct 2026

Consumer smartwatch helps identify adults with severe sleep apnea

New research suggests that a consumer smartwatch can help identify adults with moderate-to-severe obstructive sleep apnea, offering a way to screen for a common sleep disorder that often goes undiagnosed.

13 Oct 2026

Major trial seeks to test semaglutide on adults with alcohol and opioid use disorder

The Center for Addiction Science, Policy and Research (CASPR) and the Allegheny County Department of Human Services are preparing to launch a major $13.3 million randomized controlled trial to test whether weekly semaglutide, as an additional support to existing care, can reduce alcohol and opioid use and reduce criminal-justice involvement while improving employment, health, and housing outcomes among people at elevated risk of criminal-justice involvement.

13 Oct 2026

New study tracks how eating behaviors vary with age, sex and body weight

Eating behavior varies with age and body weight. A University of Oulu study found that emotional and uncontrolled eating are more pronounced in younger adults, while cognitive restraint is more common among older people. Sex and body weight also influence which eating behaviors are typical.

12 Oct 2026

Diet drinks showed no clear weight-loss edge over water after two years

In a two-year randomized trial combining assisted weight management with an unassisted follow-up year, completers maintained average weight losses of 4.8 kg with diet drinks and 3.7 kg with water. Researchers found no significant difference between groups, but fewer than half of the 493 participants completed follow-up.

11 Oct 2026

Stopping GLP-1 drugs often brings weight back. A small trial suggests ways to slow it

In a randomized pilot trial of 39 adults, researchers found that participants receiving medically tailored meals or Noom regained about 3.6% of their body weight over four months after stopping GLP-1 therapy, compared with about 11% under usual care. These exploratory findings suggest structured support may slow early weight regain, but the small sample and short follow-up leave lasting benefits uncertain.

11 Oct 2026

GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases.

1 Oct 2026

Study examines the real-world use of GLP-1 RA drugs in children and young people

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

30 Sep 2026

Petrelintide produces double-digit weight loss with fewer side effects

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

29 Sep 2026

University of Liverpool study tracks long-term impact of non-nutritive sweetened soft drinks

Researchers at the University of Liverpool have conducted the longest and most comprehensive randomized controlled trial on non-nutritive sweetened (NNS) soft drinks.

29 Sep 2026